SCHEMBL23134658

SCHEMBL23134658

Nc1ccc(N2CCC(C=O)CC2)nc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GRIN2D O15399 1/20 0.46
▸ GRIN3B O60391 1/20 0.46
▸ GRIN1 Q05586 1/20 0.46
▸ GRIN2A Q12879 1/20 0.46
▸ GRIN2B Q13224 1/20 0.46
▸ GRIN2C Q14957 1/20 0.46
▸ GRIN3A Q8TCU5 1/20 0.46
▸ KDM4E B2RXH2 1/20 0.41
▸ ABL1 P00519 1/20 0.41
▸ LMNA P02545 1/20 0.41
▸ MAPT P10636 2/20 0.40
▸ OGA O60502 1/20 0.38
▸ CHRNA7 P36544 1/20 0.37
▸ KMT2A Q03164 1/20 0.37
▸ JAK2 O60674 2/20 0.36
▸ JAK1 P23458 2/20 0.36
▸ JAK3 P52333 2/20 0.36
▸ KCNH2 Q12809 1/20 0.36
▸ GPR119 Q8TDV5 4/20 0.36
▸ HRH3 Q9Y5N1 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10224799 0.81 GPR119 (0.53) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL24735177 0.81 MAPT (0.40) KDM4EABL1LMNAMAPTKMT2A
SCHEMBL30612341 0.81 MAPT (0.40) KDM4EABL1LMNAMAPTKMT2A
SCHEMBL24670654 0.81 AKR1C3 (0.48) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL20124827 0.80 HRH3 (0.54) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL31747496 0.80 HRH3 (0.55) KDM4EABL1LMNAJAK2JAK1
SCHEMBL19998348 0.79 GRIN2D (0.59) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL29499599 0.79 GRIN2D (0.59) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL31289277 0.79 GPR119 (0.56) KDM4EJAK2JAK1JAK3KCNH2
SCHEMBL12832973 0.79 MAPT (0.57) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230150973-A1 NOVEL UREAS HAVING ANDROGEN RECEPTOR DEGRADATION ACTIVITY AND USES THEREOF ACCUTAR BIOTECHNOLOGY INC. (US) 2023-05-18 — — US disclosed
WO-2021061642-A1 NOVEL UREAS HAVING ANDROGEN RECEPTOR DEGRADATION ACTIVITY AND USES THEREOF ACCUTAR BIOTECHNOLOGY INC. (US) 2021-04-01 — — WO disclosed
US-20210087170-A1 NOVEL UREAS HAVING ANDROGEN RECEPTOR DEGRADATION ACTIVITY AND USES THEREOF ACCUTAR BIOTECHNOLOGY INC. (US) 2021-03-25 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210087170-A1 NOVEL UREAS HAVING ANDROGEN RECEPTOR DEGRADATION ACTIVITY AND USES THEREOF AR, UTS2R, ESRRA GRIN2D 4739/4885GRIN3B 4296/4885GRIN1 4100/4885
US-20230150973-A1 NOVEL UREAS HAVING ANDROGEN RECEPTOR DEGRADATION ACTIVITY AND USES THEREOF AR, UTS2R, ESRRA GRIN2D 4739/4885GRIN3B 4296/4885GRIN1 4100/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback